Building a leading microbiome company in oncology

We are a clinical-stage microbiome therapeutics company aiming to
improve survival in cancer.

See News

Corporate profile

We are a clinical-stage microbiome therapeutics company aiming to restore and modulate patient-microbiome symbiosis to improve survival in cancer. To do so, we are developing a novel class of microbiome drug candidates: Microbiome Ecosystem Therapies (MET). MET are high-diversity, high-richness, indication-specific products aiming to leverage the full functional diversity of a microbiome ecosystem. Our MET drug development platform leverages gutPrint®, our proprietary AI-based computational biology and our proprietary cGMP manufacturing capacities to deliver innovative new drugs for the treatment of graft-vs-host-disease , the prevention of complications of HSCT for patients with liquid tumors and the improvement of response to immune checkpoint inhibitors in solid tumors. Our team combines expertise ranging from microbiology to data science to oncology and benefits from the commitment of world-leading scientists.

Press Releases

Press Releases

May 26, 2023: MaaT Pharma Announces Combined General Meeting on June 19, 2023 and the Availability of the Preparatory Documents

MaaT Pharma Announces Combined General Meeting on June 19, 2023 and the Availability of the Preparatory…
Press Releases
May 9, 2023: MaaT Pharma Announces Cash and Revenues for the First Quarter of 2023
Press Releases
May 3, 2023: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital
Press Releases
April 24, 2023: MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
Press Releases
April 11, 2023: MaaT Pharma to Present Clinical Data for MaaT013 and MaaT033 at 49th EBMT Annual Meeting

See more

Media Coverage

Media

April 28, 2023: Microbiome Times – FDA Lifts Hold on Maat Pharma’s Phase 3 Investigational NDA for MaaT013

Media
April 28, 2023: Microbiome Post – MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
Media
April 25, 2023: BioPharma Reporter – FDA lifts 18-month clinical hold on MaaT Pharma’s microbiome therapeutic
Media
April 24, 2023 : Endpoints News – FDA lifts nearly two-year hold on MaaT Pharma’s microbiome therapy, opens door to PhIII
Media
April 24, 2023: The Pharma Letter – FDA lifts clinical hold of MaaT Pharma’s lead microbiome therapeutic trial
Media
March 2023: Pharmaphorum – The gut microbiome: the next breakthrough in cancer?

See more

Posters

Posters

Restoration of gut microbiota diversity with oral pooled fecal microbiotherapy in acute myeloid leukemia patients after intensive chemotherapy: the phase 1b CIMON trial

Posters
Pooled allogenic fecal microbiotherapy MaaT013 for the treatment of steroid-refractory gastrointestinal acute graft-versus-host disease: results from the phase IIa HERACLES study and expanded access program
Posters
Pooling of faecal material results in standardized and high-richness microbiotherapy products MaaT013 and MaaT033
Posters
Development of a culture manufacturing process preserving the profile of gut microbiota for therapeutic purposes
Posters
EBMT 2020: Successful and safe treatment of intestinal Graft-versus-Host Disease (GvHD) with pooled-donor full ecosystem microbiota therapeutics
Posters
ASH 2019: Successful and safe treatment of intestinal Graft-versus-Host Disease (GvHD) with pooled-donor full ecosystem microbiota therapeutics

Videos

Videos

R&D Day 2022 replay

On June 7th, 2022, MaaT Pharma hosted its virtual R&D Day to share the latest…
Videos
H.C Wainwright Bioconnect 2022 conference replay
Videos
Investors Webcast – 12/13/21 – Corporate Update
Videos
IABS Bioaster – FMT WEBINAR
Videos
EY : Prix de l’Entrepreneur de l’Année
Videos
Hybridays 2021: Savita BERNAL, Chief Business Officer at MaaT Pharma